Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies.
Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. Currently, we are utilizing a peptide nanoscaffold based approach for treating COVID-19 without a gene therapy component, with the goal of creating a combined antidote-vaccine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type.
Company Details
- Employees
- 12
- Founded
- -
- Address
- 650 5th St, San Francisco,california,united States
- Industry
- Biotechnology
- Website
- ligandal.com
- HQ
- San Francisco, California
Ligandal Questions
Ligandal's website is ligandal.com
Ligandal's LinkedIn profile is https://www.linkedin.com/company/ligandal
Ligandal has
12 employees.
View email and phone details for 12
employees at Ligandal.
Ligandal's industry is
Biotechnology
Ligandal's top competitors are
Precigenetics,
Hyper Accelerator,
Verantos,
Plus None,
Prism Ai Therapeutics,
Hyperstition Incorporated,
Terran Applied Sciences,
Sama Therapeutics,
Rowzzy Co,
Polypid Ltd..
Ligandal's categories are Biotechnology
Ligandal's founding year is 2014
